Related Experiment Video
Updated: Sep 20, 2026

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
The CCT6A paradigm: biomarker potential and therapeutic challenges in oncology and beyond
Rui-Hang Du1, Yi Cheng1, Zi-Peng Ren1
1Precision Medicine Laboratory for Chronic Non-Communicable Diseases of Shandong Province, Institute of Precision Medicine, Jining Medical University, Jining, 272067, China.
Abstract:
Chaperonin Containing TCP1 Subunit 6A (CCT6A), a structurally conserved core subunit of the eukaryotic CCT/TRiC complex, orchestrates ATP-dependent protein folding, cytoskeletal dynamics, and stress-responsive adaptation, reflecting its indispensable role in cellular homeostasis. Emerging evidence highlights CCT6A as a multifaceted oncogenic driver across diverse malignancies (such as colorectal cancer and hepatocellular carcinoma), through metabolic reprogramming, stabilization of oncoproteins, and immunosuppression. Its overexpression correlates with aggressive phenotypes, therapeutic resistance, and poor prognosis, positioning it as a robust diagnostic and prognostic biomarker. Beyond oncology, CCT6A also contributes to autoimmune diseases, pulmonary fibrosis, and acute kidney injury. Despite its therapeutic potential, key challenges include unresolved context-dependent signaling mechanisms, absence of subunit-specific inhibitors, and the need to reconcile CCT6A targeting with preservation of CCT complex functionality. This review delineates CCT6A's multifunctional roles in oncogenesis and immune-metabolic dysregulation, critically evaluates its biomarker potential, and proposes targeted therapeutic frameworks to refine precision medicine paradigms across diverse disease landscapes.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistent Cancers
Tumor Immunotherapy
Cancer
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
